Committee on Energy and Commerce U.S. House of Representatives

Witness Disclosure Requirement – "Truth in Testimony" Required by House Rule XI, Clause 2(g)(5)

1. Your Name:

Deepa R. Camenga, MD MHS FAAP

2. Your Title:

Chair, Committee on Substance Use and Prevention, American Academy of Pediatrics

3. The Entity(ies) You are Representing:

American Academy of Pediatrics

4. Are you testifying on behalf of the Federal, or a State or local government entity? (If "Yes," skip Item 5 and Item 6.)

Yes No

5. Grants, Contracts, and Payments

a. Please list any <u>Federal grants or contracts</u> that you or the entity(ies) you represent have received <u>on or after January 1, 2023</u>. Only grants, contracts, or payments related to the subject matter of the hearing must be listed.

Dr. Camenga:

Agency: Health Resources and Service Administration

Title: Integrated Substance Use Disorder (SUD) Training Program (Substance Use Skills Training for

Integrated Care)

Role: Adolescent Addiction Medicine Liaison

Percent Effort: 10%

Total costs: \$2,567,104.00

Project period: 07/01/2023 - 06/30/2028

Agency: Substance Abuse and Mental Health Services Administration

Title: Responsive Integration of Substance Use Education (PCSS-U Project RISE)

Role: Adolescent Addiction Medicine Liaison

Percent Effort: 5%

Total costs: \$553,756.00

Project period: 09/30/2024 - 09/29/2026

Agency: Health Resources Service Administration

Title: Primary Care Training and Enhancement: Collaborative Behavioral Health and Addiction Medicine

in Primary Care (CHAMP)

Role: Adolescent Addiction Medicine Liaison

Percent Effort: 10%

Total costs: \$1,976,565.00 Project Period: 07/01/19-06/30/24

Agency: NIH/NIDA

Title: Trajectory Outcomes of Teens that Ride with Impaired Drivers & Drive Impaired

Role: Co-Investigator

Percent Effort: 5%

Direct Costs per year: \$371,395 Project Period: 09/01/2018-08/31/2023 Agency: NIH/NIDA

ID: 2023 NIH Challenge Award

Title: "Making Substance Use Prevention as Easy as Vaccination! Leveraging Machine Learning to Deliver

Personalized Substance Use Prevention in Primary Care"

Role: Challenge Winner (Team Leader), '

Total Award: \$25,000

American Academy of Pediatrics:

Agency: Substance Abuse and Mental Health Service Administration (Subaward from American Academy of

Addiction Psychiatry)

Title: Opioid Response Network: Collaborating, Advancing, Responding, Educating (CARE)

Amount: \$80,000

Agency: Health Resources and Services Administration Title: Telehealth Technology-Enabled Learning Program

Amount: 5 year grant at \$475,000/year, 09/30/21 - 09/29/26. Portion of funds awarded after 01/01/23 is

\$1,425,000

Funder: Centers for Disease Control and Prevention

Project Title: Let's Talk About it: Reducing Mental Health Stigma through Key Opinion Leaders

Amount: \$300,000

Funder: Centers for Disease Control and Prevention

Project Title: Improving Outcomes Related to Perinatal Health and Substance Use

Amount: \$585,000

Funder: Centers for Disease Control and Prevention

Title: Pediatric Public Health Partnership on Fetal Alcohol Spectrum Disorders

Amount: \$500,000

Funder: Centers for Disease Control and Prevention

Title: Improving Outcomes to Opioid Misuse through Strategies Addressing Clinical Care for Women and

Infants

Amount: \$1,300,000

Funder: Centers for Disease Control and Prevention

Title: National Partnerships to Address Prenatal Alcohol and Other Substance Use and Fetal Alcohol Spectrum

Disorders

Amount: \$733,750

Funder: Administration for Children and Families

Title: NCECHW - Opioids and Reducing Child Incidents

Amount: \$535,000

(See next page)

	b. Please list any contracts or payments originating with a foreign government that you or the entity(ies) you represent have received on or after January 1, 2023. Only grants, contracts, or payments related to the subject matter of the hearing must be listed.					
6.	N/A Are you a fiduciary (i.e., authorized to act on behalf of or for the benefit of) for any entity that has an interest in the subject matter of the hearing?	Yes	No x			
7.	Please attach your curriculum vitae to your completed disclosure form.					

Signature:		Date:February 4, 2025	
_			